Vladimir Tolmachev

List of Publications by Citations

296 papers	9,419 citations	51 h-index	80 g-index
313 ext. papers	10,428 ext. citations	5.2 avg, IF	6.11 L-index

#	Paper	IF	Citations
296	Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. *FEBS Letters*, **2010**, 584, 2670-80	3.8	439
295	Tumor imaging using a picomolar affinity HER2 binding affibody molecule. *Cancer Research*, **2006**, 66, 4339-48	10.1	405
294	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. *Journal of Nuclear Medicine*, **2010**, 51, 892-7	8.9	233
293	Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. *Cancer Research*, **2007**, 67, 2773-82	10.1	179
292	First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. *Journal of Nuclear Medicine*, **2014**, 55, 730-5	8.9	162
291	Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. *Cancer Research*, **2007**, 67, 2178-86	10.1	161
290	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. *Theranostics*, **2016**, 6, 262-71	12.1	146
289	Selection and characterization of HER2/neu-binding affibody ligands. *Protein Engineering, Design and Selection*, **2004**, 17, 455-62	1.9	144
288	Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. *Journal of Biological Chemistry*, **2011**, 286, 5234-41	5.4	129
287	On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. *Journal of Nuclear Medicine*, **2009**, 50, 417-25	8.9	124
286	Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. *Journal of Molecular Biology*, **2008**, 376, 1388-402	6.5	118
285	Design of an optimized scaffold for affibody molecules. *Journal of Molecular Biology*, **2010**, 398, 232-47	6.5	116
284	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. *Expert Opinion on Biological Therapy*, **2007**, 7, 555-68	5.4	106
283	Imaging of HER-2 overexpression in tumors for guiding therapy. *Current Pharmaceutical Design*, **2008**, 14, 2999-3019	3.3	102
282	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 613-22	8.8	97
281	Pretargeted Imaging and Therapy. *Journal of Nuclear Medicine*, **2017**, 58, 1553-1559	8.9	96
280	Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. *Journal of Nuclear Medicine*, **2009**, 50, 274-83	8.9	91

279	Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. *Journal of Nuclear Medicine*, **2009**, 50, 781-9	8.9	90
278	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. *Lancet Oncology, The*, **2010**, 11, 992-1000	21.7	88
277	(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. *Bioconjugate Chemistry*, **2007**, 18, 1956-64	6.3	88
276	Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. *Journal of Nuclear Medicine*, **2005**, 46, 1881-8	8.9	88
275	VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. *Nature Communications*, **2016**, 7, 11017	17.4	77
274	Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. *Bioconjugate Chemistry*, **2008**, 19, 235-43	6.3	76
273	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. *European Journal of Nuclear Medicine and Molecular Imaging*, **2007**, 34, 722-733	8.8	76
272	In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. *Cancer Biotherapy and Radiopharmaceuticals*, **2005**, 20, 239-48	3.9	75
271	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. *Journal of Nuclear Medicine*, **2010**, 51, 1131-8	8.9	73
270	111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. *Journal of Nuclear Medicine*, **2006**, 47, 846-53	8.9	72
269	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. *Journal of Nuclear Medicine*, **2018**, 59, 885-891	8.9	71
268	Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. *Biochimica Et Biophysica Acta - General Subjects*, **2010**, 1800, 487-510	4	71
267	A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 1356-67	8.8	71
266	Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. *Journal of Nuclear Medicine*, **2013**, 54, 961-8	8.9	69
265	99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. *European Journal of Nuclear Medicine and Molecular Imaging*, **2007**, 34, 1843-53	8.8	69
264	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. *Journal of Nuclear Medicine*, **2016**, 57, 867-71	8.9	69
263	Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. *Journal of Nuclear Medicine*, **2011**, 52, 461-9	8.9	68
262	Engineering of affibody molecules for therapy and diagnostics. *Methods in Molecular Biology*, **2012**, 899, 103-26	1.4	67

261	Production of 76Br by a low-energy cyclotron. *Applied Radiation and Isotopes*, **1998**, 49, 1537-1540	1.7	66
260	HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [□□(m)Tc(CO)]□(+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. *Bioconjugate Chemistry*, **2010**, 21, 2013-22	6.3	63
259	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. *Journal of Nuclear Medicine*, **2006**, 47, 512-9	8.9	63
258	Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. *Journal of Nuclear Medicine*, **2012**, 53, 953-60	8.9	61
257	Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. *Current Medicinal Chemistry*, **2010**, 17, 2636-55	4.3	59
256	Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. *Journal of Nuclear Medicine*, **2012**, 53, 146-53	8.9	58
255	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 2245-55	8.8	58
254	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 631-8	8.8	58
253	Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. *British Journal of Haematology*, **1999**, 104, 296-302	4.5	57
252	Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. *Bioconjugate Chemistry*, **2013**, 24, 1144-53	6.3	56
251	Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. *Cancer Immunology Research*, **2014**, 2, 80-90	12.5	55
250	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. *Drug Discovery Today*, **2012**, 17, 1224-32	8.8	55
249	[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. *European Journal of Nuclear Medicine and Molecular Imaging*, **2005**, 32, 1457-62	8.8	52
248	Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. *Current Opinion in Drug Discovery & Development*, **2007**, 10, 167-75		52
247	Affibody-mediated PET imaging of HER3 expression in malignant tumours. *Scientific Reports*, **2015**, 5, 15226	4.9	51
246	In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. *Bioconjugate Chemistry*, **2007**, 18, 549-58	6.3	51
245	Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. *PLoS ONE*, **2013**, 8, e62791	3.7	51
244	Update: affibody molecules for molecular imaging and therapy for cancer. *Cancer Biotherapy and Radiopharmaceuticals*, **2007**, 22, 573-84	3.9	50

243	Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. *British Journal of Haematology*, **2003**, 120, 853-9	4.5	50
242	Radionuclide molecular imaging using Affibody molecules. *Current Pharmaceutical Biotechnology*, **2010**, 11, 581-9	2.6	49
241	Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase. *International Journal of Biochemistry and Cell Biology*, **1999**, 31, 291-301	5.6	48
240	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. *Cancer Research*, **2015**, 75, 4364-71	10.1	47
239	HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. *Journal of Medicinal Chemistry*, **2013**, 56, 4966-74	8.3	47
238	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 692-701	8.8	47
237	Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. *Bioconjugate Chemistry*, **2005**, 16, 1547-55	6.3	47
236	The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin. *Molecules*, **2014**, 19, 10455-72	4.8	46
235	Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. *Nuclear Medicine and Biology*, **2004**, 31, 425-33	2.1	46
234	Elimination of stabilised hyaluronan from the knee joint in healthy men. *Clinical Pharmacokinetics*, **2002**, 41, 603-13	6.2	46
233	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. *Theranostics*, **2016**, 6, 93-103	12.1	46
232	Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. *Journal of Nuclear Medicine*, **2016**, 57, 431-6	8.9	44
231	Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts. *PLoS ONE*, **2013**, 8, e70028	3.7	44
230	[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. *Cancer Research*, **2007**, 67, 326-31	10.1	44
229	Specific uptake of an amyloid-β protofibril-binding antibody-tracer in APP transgenic mouse brain. *Journal of Alzheimer's Disease*, **2013**, 37, 29-40	4.3	43
228	Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. *Journal of Medicinal Chemistry*, **2011**, 54, 3817-26	8.3	43
227	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 531-9	8.8	42
226	Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. *Journal of Nuclear Medicine*, **2012**, 53, 90-7	8.9	41

225	Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. *Bioconjugate Chemistry*, **2008**, 19, 2568-76	6.3	41
224	Polyhedral Boron Compounds as Potential Linkers for Attachment of Radiohalogens to Targeting Proteins and Peptides. A Review. *Collection of Czechoslovak Chemical Communications*, **2002**, 67, 913-935		41
223	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. *International Journal of Oncology*, **2016**, 48, 1325-32	4.4	41
222	Imaging of platelet-derived growth factor receptor expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. *Journal of Nuclear Medicine*, **2014**, 55, 294-300	8.9	40
221	The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. *Nuclear Medicine and Biology*, **2015**, 42, 446-454	2.1	40
220	In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. *PLoS ONE*, **2013**, 8, e81932	3.7	40
219	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1864-73	8.8	40
218	Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1450-9	8.8	38
217	Targeting peptides and positron emission tomography. *Biopolymers*, **2002**, 66, 381-92	2.2	38
216	Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with Ga and In via maleimido derivatives of DOTA and NODAGA. *Bioconjugate Chemistry*, **2013**, 24, 1102-9	6.3	37
215	(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 260-9	8.8	37
214	Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. *Current Medicinal Chemistry*, **2003**, 10, 2447-60	4.3	37
213	Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI). *Nuclear Medicine and Biology*, **2004**, 31, 205-11	2.1	36
212	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 481-92	8.8	35
211	Gallium-68-labeled affibody molecule for PET imaging of PDGFR expression in vivo. *Molecular Pharmaceutics*, **2014**, 11, 3957-64	5.6	34
210	Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. *Nuclear Medicine and Biology*, **2000**, 27, 827-35	2.1	34
209	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. *Journal of Nuclear Medicine*, **2018**, 59, 1092-1098	8.9	33
208	Affibody Molecules as Targeting Vectors for PET Imaging. *Cancers*, **2020**, 12,	6.6	32

207	110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. *Journal of Nuclear Medicine*, **2002**, 43, 1391-7	8.9	32
206	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. *Bioconjugate Chemistry*, **2016**, 27, 716-26	6.3	31
205	[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 439-49	8.8	31
204	Novel chemoselective (18)F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions. *Chemical Communications*, **2016**, 52, 6083-6	5.8	31
203	Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. *Bioconjugate Chemistry*, **2012**, 23, 1661-70	6.3	30
202	Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solution using Chloramine-T. *Radiochimica Acta*, **2002**, 90, 229-235	1.9	30
201	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 1337-1346	8.8	29
200	Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. *Bioconjugate Chemistry*, **1999**, 10, 338-45	6.3	29
199	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. *Journal of Controlled Release*, **2018**, 288, 84-95	11.7	29
198	Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting. *Bioconjugate Chemistry*, **2015**, 26, 1724-36	6.3	28
197	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. *Journal of Nuclear Medicine*, **2018**, 59, 93-99	8.9	28
196	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. *Molecular Pharmaceutics*, **2016**, 13, 1668-78	5.6	28
195	Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. *Protein Expression and Purification*, **2011**, 76, 127-35	2	28
194	High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T. *Nuclear Medicine and Biology*, **1999**, 26, 923-9	2.1	28
193	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. *Scientific Reports*, **2017**, 7, 5961	4.9	27
192	Methods for radiolabelling of monoclonal antibodies. *Methods in Molecular Biology*, **2014**, 1060, 309-30	1.4	26
191	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. *Nuclear Medicine and Biology* **2011**, 38, 1093-102	2.1	26
190	The influence of Bz-DOTA and CHX-A''DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1460-8	8.8	26

189	High yield [125I]iodide-labeling of iodinated carboranes by palladium-catalyzed isotopic exchange. *Journal of Organometallic Chemistry*, **2003**, 680, 188-192	2.3	26
188	114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide. *Nuclear Medicine and Biology*, **2000**, 27, 183-8	2.1	26
187	Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. *Oncology Reports*, **2015**, 34, 1042-8	3.5	25
186	Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. *Nuclear Medicine and Biology*, **2010**, 37, 539-46	2.1	25
185	Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. *Bioconjugate Chemistry*, **2011**, 22, 894-902	6.3	25
184	Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography. *British Journal of Haematology*, **1999**, 104, 288-95	4.5	25
183	Phase I Study of Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 493-499	8.9	25
182	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. *International Journal of Molecular Medicine*, **2007**, 19, 285-91	4.4	25
181	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. *Molecular Pharmaceutics*, **2016**, 13, 3676-3687	5.6	24
180	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. *Contrast Media and Molecular Imaging*, **2018**, 2018, 6930425	3.2	24
179	Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde. *Bioconjugate Chemistry*, **2014**, 25, 82-92	6.3	24
178	Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule. *International Journal of Oncology*, **2015**, 46, 513-20	4.4	24
177	A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides. *Acta Oncologica*, **2004**, 43, 264-75	3.2	24
176	Cyclic versus Noncyclic Chelating Scaffold for Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. *Molecular Pharmaceutics*, **2018**, 15, 175-185	5.6	24
175	Optimal composition and position of histidine-containing tags improves biodistribution of Tc-labeled DARPin G3. *Scientific Reports*, **2019**, 9, 9405	4.9	23
174	Evaluation of a maleimido derivative of CHX-A''DTPA for site-specific labeling of affibody molecules. *Bioconjugate Chemistry*, **2008**, 19, 1579-87	6.3	23
173	Combined effect of gefitinib (IressaZD1839) and targeted radiotherapy with 211At-EGF. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 1348-56	8.8	23
172	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. *Molecular Pharmaceutics*, **2019**, 16, 995-1008	5.6	23

171	Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. *Oncology Reports*, **2007**, 17, 1141-7	3.5	23
170	Evaluation of the first Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. *Nuclear Medicine and Biology*, **2017**, 45, 15-21	2.1	22
169	Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET. *Nuclear Medicine and Biology*, **2000**, 27, 837-43	2.1	22
168	Positron emission tomography and radioimmunotargeting--general aspects. *Acta Oncologica*, **1999**, 38, 335-41	3.2	22
167	Rapid separation of gallium from zinc targets by thermal diffusion. *Applied Radiation and Isotopes*, **1996**, 47, 297-299	1.7	22
166	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. *Contrast Media and Molecular Imaging*, **2017**, 2017, 6873684	3.2	21
165	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. *International Journal of Oncology*, **2016**, 49, 1185-94	4.4	21
164	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. *International Journal of Oncology*, **2016**, 49, 2285-2293	4.4	21
163	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A?DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. *Experimental and Therapeutic Medicine*, **2011**, 2, 523-528	2.1	21
162	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. *Nuclear Medicine and Biology*, **2005**, 32, 613-22	2.1	21
161	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. *International Journal of Oncology*, **2016**, 48, 2124-34	4.4	20
160	188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. *Journal of Nuclear Medicine*, **2014**, 55, 1842-8	8.9	20
159	Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group. *Journal of Radioanalytical and Nuclear Chemistry*, **2003**, 256, 191-197	1.5	20
158	Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. *International Journal of Molecular Medicine*, **2007**, 20, 397-404	4.4	20
157	Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. *International Journal of Oncology*, **2015**, 47, 601-9	4.4	19
156	Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. *Amino Acids*, **2015**, 47, 303-15	3.5	19
155	In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. *Nuclear Medicine and Biology*, **2006**, 33, 991-8	2.1	19
154	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. *EJNMMI Radiopharmacy and Chemistry*, **2020**, 5, 16	5.8	19

153	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. *Theranostics*, **2018**, 8, 4462-4476	12.1	19
152	Production of 61Cu from a natural nickel target. *Applied Radiation and Isotopes*, **1998**, 49, 79-81	1.7	18
151	Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. *Carbohydrate Research*, **2005**, 340, 15-24	2.9	18
150	In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2005**, 32, 1296-304	8.8	18
149	Conjugate chemistry and cellular processing of EGF-dextran. *Acta Oncologica*, **1999**, 38, 313-21	3.2	18
148	Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse. *Scientific Reports*, **2018**, 8, 5220	4.9	17
147	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. *Tumor Biology*, **2012**, 33, 641-51	2.9	17
146	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. *International Journal of Oncology*, **2012**, 40, 1677-82	4.4	17
145	Synthesis of N-Succinimidyl 4-[76Br]Bromobenzoate and its Use in Conjugation Labelling of Macromolecules.. *Acta Chemica Scandinavica*, **1999**, 53, 508-512		17
144	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. *Scientific Reports*, **2017**, 7, 43118	4.9	16
143	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3912-4	2.9	16
142	Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. *Journal of Neuro-Oncology*, **2006**, 77, 33-45	4.8	16
141	Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. *Bioconjugate Chemistry*, **2003**, 14, 805-10	6.3	16
140	Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry. *Acta Oncologica*, **1999**, 38, 343-9	3.2	16
139	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of Ga-Labeled Tracers. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	15
138	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. *Scientific Reports*, **2018**, 8, 2998	4.9	15
137	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. *Molecular Pharmaceutics*, **2018**, 15, 3394-3403	5.6	15
136	[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. *Cancer Biotherapy and Radiopharmaceuticals*, **2003**, 18, 643-54	3.9	15

135	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2000**, 43, 251-260	1.9	15
134	Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties. *Medical Physics*, **1999**, 26, 249-58	4.4	15
133	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 134, 37-48	5.7	15
132	Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26. *International Journal of Cancer*, **2019**, 145, 3347-3358	7.5	14
131	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. *Amino Acids*, **2012**, 42, 1975-85	3.5	14
130	Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody. *Biopolymers*, **2009**, 92, 116-23	2.2	14
129	Differences in radiosensitivity between three HER2 overexpressing cell lines. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 1179-91	8.8	14
128	Separation of arsenic from germanium oxide targets by dry distillation. *Journal of Radioanalytical and Nuclear Chemistry*, **2001**, 247, 61-66	1.5	14
127	Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy. *Physics in Medicine and Biology*, **2002**, 47, 615-29	3.8	14
126	Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. *Bioconjugate Chemistry*, **1999**, 10, 938-46	6.3	14
125	Rapid separation of 110In from enriched Cd targets by thermal diffusion. *Applied Radiation and Isotopes*, **1995**, 46, 859-863	1.7	14
124	Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. *PLoS ONE* , **2014**, 9, e107483	3.7	14
123	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. *Cells*, **2018**, 7,	7.9	14
122	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. *Cancers*, **2019**, 11,	6.6	13
121	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. *Scientific Reports*, **2019**, 9, 655	4.9	13
120	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. *Biomaterials*, **2019**, 203, 73-85	15.6	13
119	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. *European Journal of Medicinal Chemistry*, **2014**, 87, 519-28	6.8	13
118	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. *Scientific Reports*, **2017**, 7, 14780	4.9	13

117	Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. *International Journal of Oncology*, **2014**, 44, 1998-2008	4.4	13
116	Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay. *Tumor Biology*, **2007**, 28, 253-63	2.9	13
115	Synthesis and radioiodination of 7-(3?-ammoniopropyl)-7,8-dicarba-nido-undecaborate(-1), (ANC). *Journal of Labelled Compounds and Radiopharmaceuticals*, **2004**, 47, 557-569	1.9	13
114	Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. *Current Pharmaceutical Design*, **2014**, 20, 2275-92	3.3	13
113	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 491-501	3.9	13
112	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. *International Journal of Biological Macromolecules*, **2020**, 145, 216-225	7.9	13
111	CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. *Scientific Reports*, **2019**, 9, 18898	4.9	13
110	Preclinical Evaluation of [Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. *Cells*, **2018**, 7,	7.9	13
109	Indirect Radioiodination of DARPin G3 Using N-succinimidyl--Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	12
108	Selection of the optimal macrocyclic chelators for labeling with In and Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 140, 109-120	5.7	12
107	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. *Bioconjugate Chemistry*, **2016**, 27, 2678-2688	6.3	12
106	Control of growth factor binding and release in bisphosphonate functionalized hydrogels guides rapid differentiation of precursor cells in vitro. *Biomaterials Science*, **2016**, 4, 250-4	7.4	12
105	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with In and Ga. *Molecular Pharmaceutics*, **2018**, 15, 2674-2683	5.6	12
104	Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging. *Nuclear Medicine and Biology*, **2013**, 40, 378-86	2.1	12
103	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. *Nuclear Medicine and Biology*, **2012**, 39, 518-29	2.1	12
102	Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. *Nuclear Medicine and Biology*, **2011**, 38, 103-12	2.1	12
101	Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 727-9	8.8	12
100	Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. *Cancer Biotherapy and Radiopharmaceuticals*, **2002**, 17, 385-96	3.9	12

99	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of Tc-labeled anti-EGFR affibody molecules. *Amino Acids*, **2018**, 50, 981-994	3.5	11
98	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. *Pharmaceutics*, **2019**, 11,	6.4	11
97	Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates. *Molecular Imaging*, **2014**, 13,	3.7	11
96	Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. *International Journal of Oncology*, **2011**, 38, 1137-43	4.4	11
95	Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 491-501	3.9	11
94	Feasibility of palladium-catalyzed isotopic exchange between sodium [125I]I and 2-iodo-para-carborane. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2003**, 46, 623-631	1.9	11
93	Radiobromination of closo-carboranes using palladium-catalyzed halogen exchange. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2005**, 48, 195-202	1.9	11
92	Radiobromine-labelled tracers for positron emission tomography: possibilities and pitfalls. *Current Radiopharmaceuticals*, **2011**, 4, 76-89	1.8	11
91	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu Using NOTA and NODAGA. *Contrast Media and Molecular Imaging*, **2017**, 2017, 8565802	3.2	10
90	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. *International Journal of Oncology*, **2017**, 51, 1765-1774	4.4	10
89	Molecular design of radiocopper-labelled Affibody molecules. *Scientific Reports*, **2018**, 8, 6542	4.9	10
88	Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. *ChemistryOpen*, **2015**, 4, 174-82	2.3	10
87	Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. *Cancer Biotherapy and Radiopharmaceuticals*, **2012**, 27, 243-51	3.9	10
86	Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. *Human Antibodies*, **2010**, 19, 107-11	1.3	10
85	Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study. *Cancer Biotherapy and Radiopharmaceuticals*, **2008**, 23, 172-80	3.9	10
84	Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. *Laryngoscope*, **2007**, 117, 1013-8	3.6	10
83	Biodistribution of 211At-labeled humanized monoclonal antibody A33. *Cancer Biotherapy and Radiopharmaceuticals*, **2007**, 22, 480-7	3.9	10
82	[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 195-204	3.9	10

81	Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. *International Journal of Oncology*, **2016**, 48, 461-70	4.4	10
80	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. *Scientific Reports*, **2019**, 9, 17086	4.9	10
79	Increase in negative charge of Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. *Scientific Reports*, **2019**, 9, 17710	4.9	10
78	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. *Oncology Reports*, **2005**, 13, 1169-75	3.5	10
77	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. *International Journal of Oncology*, **2019**, 54, 1209-1220	4.4	9
76	Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 693-702	8.8	9
75	In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma. *Cancer Biotherapy and Radiopharmaceuticals*, **2005**, 20, 514-23	3.9	9
74	Quantification aspects of patient studies with 52Fe in positron emission tomography. *Applied Radiation and Isotopes*, **1999**, 51, 707-15	1.7	9
73	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. *Scientific Reports*, **2019**, 9, 14907	4.9	9
72	Phase I trial of Tc-(HE)-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. *Journal of Nuclear Medicine*, **2021**,	8.9	9
71	Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). *Anticancer Research*, **2006**, 26, 1217-23	2.3	9
70	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
69	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
68	Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate. *Nuclear Medicine and Biology*, **2011**, 38, 697-706	2.1	8
67	Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT. *Physics in Medicine and Biology*, **2004**, 49, 5419-32	3.8	8
66	Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2005**, 48, 855-871	1.9	8
65	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. *Scientific Reports*, **2018**, 8, 9643	4.9	8
64	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A. *International Journal of Oncology*, **2019**, 55, 309-319	4.4	7

63	Preparation, radioiodination and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides. *Journal of Radioanalytical and Nuclear Chemistry*, **2004**, 261, 107-112	1.5	7
62	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. *Cancers*, **2020**, 13,	6.6	7
61	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. *Pharmaceutics*, **2020**, 12,	6.4	7
60	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
59	Choice of Radionuclides and Radiolabelling Techniques **2008**, 145-174		7
58	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. *Anticancer Research*, **2004**, 24, 4035-41	2.3	7
57	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. *International Journal of Molecular Medicine*, **2007**, 19, 485-93	4.4	7
56	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. *Scientific Reports*, **2019**, 9, 6779	4.9	6
55	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. *Cancers*, **2019**, 11,	6.6	6
54	Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules. *Cancer Biotherapy and Radiopharmaceuticals*, **2011**, 26, 593-601	3.9	6
53	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1. *Molecules*, **2020**, 25,	4.8	6
52	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. *Scientific Reports*, **2020**, 10, 20777	4.9	6
51	Comparative Evaluation of Novel Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. *Cancers*, **2021**, 13,	6.6	6
50	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. *Seminars in Cancer Biology*, **2021**, 72, 185-197	12.7	6
49	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. *Pharmaceutics*, **2019**, 11,	6.4	5
48	125I-labeled quercetin as a novel DNA-targeted radiotracer. *Cancer Biotherapy and Radiopharmaceuticals*, **2011**, 26, 469-75	3.9	5
47	Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. *Oncology Reports*, **2007**,	3.5	5
46	Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. *Acta Oto-Laryngologica*, **2004**, 124, 1078-85	1.6	5

45	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. *Journal of Radioanalytical and Nuclear Chemistry*, **2004**, 260, 295-299	1.5	5
44	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. *European Journal of Organic Chemistry*, **2004**, 2004, 3719-3725	3.2	5
43	Feasibility of isotopic exchange in the system [125I] iodide - undecahydro-iodo-closo-dodecaborate(2-) anion. *Journal of Radioanalytical and Nuclear Chemistry*, **2003**, 256, 67-71	1.5	5
42	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. *Current Medicinal Chemistry*, **2020**, 27, 7090-7111	4.3	5
41	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. *Applied Materials Today*, **2021**, 25, 101199	6.6	5
40	Basic and practical concepts of radiopharmaceutical purification methods. *Drug Discovery Today*, **2019**, 24, 315-324	8.8	5
39	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. *Pharmaceutics*, **2020**, 12,	6.4	4
38	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
37	Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. *EJNMMI Research*, **2020**, 10, 21	3.6	4
36	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. *Bulletin of Siberian Medicine*, **2021**, 20, 23-30	0.4	4
35	Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga]Ga-NOTA-PEG-RM26. *Scientific Reports*, **2021**, 11, 3631	4.9	4
34	The Use of a Non-Conventional Long-Lived Gallium Radioisotope Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. *Pharmaceutics*, **2021**, 13,	6.4	4
33	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. *Cancers*, **2021**, 13,	6.6	4
32	Diffusion-based separation methods: Dry distillation of zinc, cadmium and mercury isotopes from irradiated targets. *Applied Radiation and Isotopes*, **1997**, 48, 565-569	1.7	3
31	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. *International Journal of Molecular Medicine*, **2007**, 19, 285	4.4	3
30	In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. *Cancer Biotherapy and Radiopharmaceuticals*, **2007**, 22, 585-96	3.9	3
29	Optimization of Iodination of [125I]-N-Succinimidyl-Para-Iodobenzoate Using Chloramine-T for Labeling of Proteins. *Journal of Radioanalytical and Nuclear Chemistry*, **2000**, 246, 207-213	1.5	3
28	Targeted nuclear medicine. Seek and destroy.. *Russian Chemical Reviews*, **2022**, 91,	6.8	3

27	Preclinical Evaluation of Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
26	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. *Cancers*, **2021**, 13,	6.6	3
25	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. *Biomaterials*, **2021**, 266, 120381	15.6	3
24	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. *Oncology Reports*, **2019**, 41, 534-542	3.5	3
23	Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting. *Methods in Molecular Biology*, **2020**, 2105, 283-304	1.4	3
22	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. *Pharmaceutics*, **2020**, 12,	6.4	2
21	Reply: Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression **2009**, 50, 1196-1196		2
20	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. *Radiochimica Acta*, **2004**, 92, 311-315	1.9	2
19	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. *Journal of Radioanalytical and Nuclear Chemistry*, **2002**, 251, 409-412	1.5	2
18	Positron emission tomography of experimental melanoma with. *Nuclear Medicine and Biology*, **2000**, 27, 845-9	2.1	2
17	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. *Pharmaceutics*, **2021**, 13,	6.4	2
16	Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors. *International Journal of Molecular Medicine*,	4.4	2
15	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. *Molecules*, **2020**, 25,	4.8	2
14	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. *Pharmaceutics*, **2021**, 13,	6.4	2
13	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody Molecules Lu-ABY-271 and Lu-ABY-027: Impact of DOTA Position on ABD Domain. *Pharmaceutics*, **2021**, 13,	6.4	2
12	Preclinical Evaluation of Tc-Labeled GRPR Antagonists maSSS/SES-PEG-RM26 for Imaging of Prostate Cancer. *Pharmaceutics*, **2021**, 13,	6.4	2
11	HER3 PET Imaging: Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. *Cancers*, **2021**, 13,	6.6	2
10	Separation of two labeled components of [111In] -OctreoScan by HPLC. *Journal of Radioanalytical and Nuclear Chemistry*, **2001**, 247, 95-99	1.5	1

9	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. *Pharmaceutics*, **2021**, 13,	6.4	1
8	EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT). *Siberian Journal of Oncology*, **2021**, 20, 170-178	0.3	1
7	Efficient Synthesis of [18F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission Tomography. *European Journal of Organic Chemistry*, **2020**, 2020, 6375-6381	3.2	1
6	The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36. *Molecular Medicine Reports*, **2010**, 3, 155-60	2.9	
5	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay **2005**, 27, 1355		
4	Non-invasive determination of HER2-expression in metastatic breast cancer by using 68Ga-ABY025 PET/CT.. *Journal of Clinical Oncology*, **2015**, 33, 11067-11067	2.2	
3	Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer. *Vestnik Rentgenologii I Radiologii*, **2021**, 102, 89-97	0.3	
2	Single-photon emission computerized tomography with 99mTC-DARPIN9_29 in diagnostics of breast cancer with Her2/neu overexpression: first clinical experience. *Molekulyarnaya Meditsina (Molecular Medicine)*, **2021**, 19, 41-46	0.1	
1	Phase I clinical study of a new radiopharmaceutical based on recombinant target molecules DARPin9_29 labeled with technetium-99m for radionuclide diagnosis of the Her2/neu-positive breast cancer. *Molekulyarnaya Meditsina (Molecular Medicine)*, **2021**, 19, 41-48	0.1	